Valuation : Exelixis, Inc.

Market Cap 14.62B 12.58B 11.84B 10.81B 20.23B 1,381B 20.28B 140B 54.28B 708B 54.91B 53.71B 2,282B P/E 2026 *
18.2x
P/E 2027 * 15.1x
Enterprise Value 13.88B 11.94B 11.24B 10.26B 19.2B 1,310B 19.25B 133B 51.52B 672B 52.11B 50.97B 2,166B EV / Sales 2026 *
5.44x
EV / Sales 2027 * 4.48x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.20%
1 week+8.37%
Current month+8.00%
1 month+4.07%
3 months+11.97%
6 months+42.95%
Current year+34.63%
1 week 53.43
Extreme 53.4283
59.72
1 month 49.97
Extreme 49.97
59.72
Current year 39.71
Extreme 39.71
59.72
1 year 33.76
Extreme 33.755
59.72
3 years 18.64
Extreme 18.64
59.72
5 years 14.87
Extreme 14.87
59.72
10 years 10.04
Extreme 10.04
59.72
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%+8.37%+55.78%+164.98% 14.62B
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
-3.00%-2.90%+33.13%+12.54% 25.74B
+0.86%+1.65%-7.74%-14.95% 26.06B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
+2.77%+28.22%-32.24%+1,021.34% 14.04B
Average -0.96%+3.05%+35.21%+261.96% 29.31B
Weighted average by Cap. -1.31%+1.52%+34.99%+179.70%

Financials

2026 *2027 *
Net sales 2.55B 2.2B 2.07B 1.89B 3.53B 241B 3.54B 24.42B 9.48B 124B 9.59B 9.38B 398B 2.9B 2.5B 2.35B 2.15B 4.01B 274B 4.02B 27.75B 10.77B 141B 10.89B 10.66B 453B
Net income 821M 706M 664M 607M 1.14B 77.48B 1.14B 7.85B 3.05B 39.75B 3.08B 3.01B 128B 1.01B 871M 820M 749M 1.4B 95.58B 1.4B 9.69B 3.76B 49.04B 3.8B 3.72B 158B
Net Debt -744M -641M -603M -551M -1.03B -70.29B -1.03B -7.12B -2.76B -36.06B -2.8B -2.73B -116B -1.62B -1.4B -1.31B -1.2B -2.25B -153B -2.25B -15.52B -6.02B -78.6B -6.09B -5.96B -253B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-09-04 $59.01 -0.20% 1,580,988
26-09-03 $59.13 +1.03% 2,141,585
26-09-02 $58.53 +2.88% 2,851,454
26-09-01 $56.89 +4.12% 2,413,531
26-08-31 $54.64 +0.35% 2,246,348
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
59.01USD
Average target price
53.69USD
Spread / Average Target
-9.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock